Free Trial

Roche (RHHBY) Stock Forecast & Price Target

$32.01
+0.44 (+1.39%)
(As of 05/31/2024 ET)

Roche - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Reduce
Based on 8 Analyst Ratings

Consensus Price Target

$40.00
24.96% Upside
High Forecast$40.00
Average Forecast$40.00
Low Forecast$40.00
TypeCurrent Forecast
6/3/23 to 6/2/24
1 Month Ago
5/4/23 to 5/3/24
3 Months Ago
3/5/23 to 3/4/24
1 Year Ago
6/3/22 to 6/3/23
Consensus Rating
Reduce
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
3 Buy rating(s)
Hold
5 Hold rating(s)
4 Hold rating(s)
5 Hold rating(s)
7 Hold rating(s)
Sell
2 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
2 Sell rating(s)
Consensus Price Target$40.00$40.00$40.00$48.00
Forecasted Upside24.96% Upside12.71% Upside12.71% Upside16.51% Upside
Get Roche Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for RHHBY and its competitors with MarketBeat's FREE daily newsletter.

RHHBY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RHHBY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Roche Stock vs. The Competition

TypeRocheMedical CompaniesS&P 500
Consensus Rating Score
1.88
2.70
2.49
Consensus RatingReduceModerate BuyHold
Predicted Upside24.96% Upside761.60% Upside9.98% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Forecasts and Stock Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/30/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageSell
5/17/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeSell ➝ Hold
3/4/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold
1/16/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeEqual Weight ➝ Underweight
9/12/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetMarket Perform ➝ Market Perform$45.00 ➝ $40.00+12.71%
9/5/2023Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
8/31/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
7/14/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy
3/27/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Equal Weight
2/27/2023Societe Generale
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
1/4/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
1/3/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underweight
12/14/2022UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ NeutralCHF 328 ➝ CHF 329
11/15/2022Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
11/15/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform$48.00+16.31%
9/15/2022Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 07:30 AM ET.

RHHBY Frequently Asked Questions

What is Roche's stock forecast and purchase recommendation?

According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Roche is $40.00, with a high forecast of $40.00 and a low forecast of $40.00. The consensus rating for Roche stock is Reduce based on the current 2 sell ratings, 5 hold ratings and 1 buy rating for RHHBY. Learn more on RHHBY's analyst rating history.

Do Wall Street analysts like Roche more than its competitors?

Analysts like Roche less than other "medical" companies. The consensus rating for Roche is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how RHHBY compares to other companies.

Is Roche being upgraded by Wall Street analysts?

Over the previous 90 days, Roche's stock had 1 upgrade by analysts.

Does Roche's stock price have much upside?

According to analysts, Roche's stock has a predicted upside of 12.71% based on their 12-month stock forecasts.

What analysts cover Roche?

Roche has been rated by research analysts at Argus, Deutsche Bank Aktiengesellschaft, and The Goldman Sachs Group in the past 90 days.


Stock Forecasts and Research Tools

This page (OTCMKTS:RHHBY) was last updated on 6/2/2024 by MarketBeat.com Staff

From Our Partners